Singapore, Sept. 29 -- Grunenthal, a global leader in pain management and research, and DKSH Business Unit Healthcare, a strategic healthcare business partner and leading provider of Market Expansion Services for pharmaceutical, over-the-counter (OTC), consumer health and medical device companies, have announced a new partnership agreement to bring four Grunenthal medicines, Qutenza(R), Vimovo(R), Palexia(R) and Zomig(R), to Asia-Pacific (APAC), accelerating access to innovative pain therapies in the region.

The partnership will support the availability of Grunenthal's pain medicines across eight markets in Asia-Pacific: Hong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand and Vietnam, bringing up to four new medicine...